Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression.
Cureus – April 01, 2024
Source: PubMed
Summary
A groundbreaking treatment approach using low dose ketamine shows remarkable promise for patients struggling with both borderline personality disorder (BPD) and treatment resistant depression (TRD). By targeting glutamate dysregulation and enhancing neuroplasticity through AMPA receptor activation, sublingual ketamine helped improve mood and emotional stability. The treatment increased brain-derived neurotrophic factor, leading to significant symptom reduction and better quality of life.
Abstract
Borderline personality disorder (BPD) and treatment-resistant depression (TRD) are common mental disorders that are challenging to treat. Ketamine is an N-methyl-D-aspartate receptor antagonist that has shown promise as a rapid-acting antidepressant when administered intravenously. BPD symptoms have also been demonstrated to improve with repeated intravenous administration of ketamine, and a single case report described improvement in BPD following the intranasal administration of esketamine. We present a case report of a woman with BPD and TRD who responded to treatment with very low-dose sublingual ketamine. Very low-dose sublingual ketamine may be effective for the treatment of psychiatric disorders such as BPD and/or comorbid TRD.